CrossFit, Inc. in Search of Fittest Woman and Man in Every Country
At the conclusion of the 2020 Reebok CrossFit Games Open in October, CrossFit, Inc. will find the fittest man and woman in every eligible country participating in the worldwide CrossFit Open and crown them national champions. National champions automatically qualify for the 2020 Reebok CrossFit Games, held in August in Madison, Wisconsin. There, national champions will have the chance to compete with other Games athletes for $1.6M and the title of Fittest on Earth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191007005216/en/
Afghanistan National Champion Sami Salampur smiles moments before taking the field at the opening ceremony at the 2019 Reebok CrossFit Games. (Photo: Michael Valentin / Business Wire)
What Are the CrossFit Games?
The CrossFit Games are a grueling, multi-day competition in which elite athletes, ages 14 to 60+, and teams from around the world compete in the ultimate test of fitness. The CrossFit Games are the Sport of Fitness, and well-rounded athletes train to be prepared for unknown events announced just before the competition. CrossFit movements are selected from gymnastics, powerlifting, Olympic lifting, running, rowing, and beyond.
Athletes arrive in Madison, Wisconsin, with almost no knowledge of the actual events, so their training has to cover a wider range of activities than any other professional sport. They are ranked during competition with their peers, and the winners are crowned Fittest on Earth after proving their fitness in a series of diverse events over the course of several days. The 2020 event will be the 13th annual edition of the CrossFit Games and the largest field of individual athletes ever. The total purse this year is more than $2.3M.
What Is the CrossFit Games Open?
The CrossFit Games Open is the largest fitness competition on Earth and the first of three competitions that form the CrossFit Games season: the Open, the Age Group Online Qualifier, and the Games. In the Open, hundreds of thousands of athletes from more than 15,000 CrossFit affiliates worldwide compete in a five-week test of fitness. This online competition is open to anyone in the world. Every week, from Oct. 10, 2019, to Nov. 11, 2019, athletes will complete a workout designed by CrossFit, Inc. to test cardiovascular/respiratory endurance, stamina, strength, flexibility, power, coordination, agility, balance, and accuracy.
Upon completion of the Open, the top 20 athletes worldwide, as well as the first-place male and female competitors from each eligible country, will earn invitations to compete at the 2020 Reebok CrossFit Games. Following the Open, top age group athletes from 14-17 and 35-60+ have a second online qualifier to earn an Age Group spot in the finals. Beyond these two online qualifiers, the only way for an athlete to guarantee a spot in the finals is to win one of the 28 Sanctionals™ (CrossFit competitions that are individually owned and operated).
CrossFit Games Open National Champions
The 2020 season will mark the second year in which CrossFit, Inc. awards the first-place man and woman in every eligible nation worldwide the opportunity to compete at the CrossFit Games.
In 2019, CrossFit crowned a total of 232 national champions hailing from 123 different countries. On Thursday, Aug. 1, 2019, the first day of competition in Madison, Wisconsin, 143 men and 117 women representing 114 countries took the field, becoming the most diverse field of athletes the CrossFit Games had ever seen.
From Afghanistan to Belgium, Egypt to Estonia, Kosovo to Kuwait — the National Champion Open qualifier gives athletes from nations where CrossFit is in its infancy the opportunity to evolve the sport and represent their countries on a worldwide stage.
There are virtually no barriers to entry for any athlete who wishes to represent their country at the 2020 Reebok CrossFit Games. No professional status or allegiance to a sport federation is required or even preferred. Athletes need only do the following:
- Register for the Open.
- Complete and video record all five Open workouts as prescribed over the course of the Open. Submit scores to games.crossfit.com.
Champions will be notified after the Leaderboard is set upon completion of the Open and after citizenship is verified.
About CrossFit, Inc.
CrossFit, Inc. is the developer and provider of the CrossFit® fitness program and a recognized worldwide leader in functional fitness. Founded by Greg Glassman and built on the foundations of constantly varied, high-intensity functional movements, education and collaborative competition, CrossFit-brand workouts develop strength and fitness while cultivating community and camaraderie in each of the more than 15,000 affiliated gyms in CrossFit’s global network. CrossFit, Inc. is a leading accredited certificate issuer for physical-training professionals worldwide and offers specialty certificate programs in addition to its core curriculum. CrossFit, Inc.’s health initiatives pursue an investigation into the ills of modern medicine and the willful abuse of the public’s trust in science. CrossFit, Inc. created and operates the CrossFit Games, an annual competition where elite athletes compete to be named the Fittest on Earth™. To learn more, visit www.CrossFit.com, Games.CrossFit.com, or http://www.youtube.com/CrossFitHQ.
CrossFit, Forging Elite Fitness, The Sport of Fitness and Fittest on Earth are registered trademarks or trademarks of CrossFit, Inc. in the U.S. and/or other countries.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
bitFlyer Europe and Quazard Partner to Bring First Ever Trading Competition to Botwars Ultimate Trading1.6.2020 06:00:00 CEST | Press release
Leading cryptocurrency exchange bitFlyer, is partnering with crypto-trading game developer Quazard, to bring the first ever gamified trading competition to the Botwars Ultimate Trading universe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200531005005/en/ bitFlyer and Quazard bring the first gamified trading competition to the Botwars Ultimate Trading universe (Graphic: Business Wire) The competition, which launches today, allows Botwars players to compete in a free to enter crypto-trading simulator to win real Bitcoin. This is the first trading competition to launch on Botwars, and the only live trading competition of its type. In Botwars Ultimate Trading, players need to build an army of trading robots (each representing a trade) and lead them into battle to conquer the cryptocurrency markets. Botwars is a real-time, gamified currency trading experience where you will learn new trading skills, unlock powerful new tradin
Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time1.6.2020 03:00:00 CEST | Press release
Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19. The treatment was also able to show improvement in lung lesions to a normal activity level in animal models. The pre-clinical study was conducted in an animal model in collaboration with one of the Korean National Universities, Chungbuk National University College of Medicine. The trial set out to assess the efficacy of two dosage amounts (low and high) for the antiviral antibody treatment. In comparison to the placebo-controlled group, the research team observed improved recovery in terms of clinical symptom scores such as runny nose, cough and body aches, after the first day of treatment. From the fifth day, significant clinical remission was observed. Reverse transcriptase polymerase chain reaction (RT-PCR) measurement and cell culture-based viral diagnosis were used to a
Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CEST | Press release
Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo